<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137752">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01755481</url>
  </required_header>
  <id_info>
    <org_study_id>327727-2</org_study_id>
    <nct_id>NCT01755481</nct_id>
  </id_info>
  <brief_title>Feeding Infant Formula With Added Probiotics and Whey Protein Concentrate</brief_title>
  <official_title>Feeding Infant Formula With Added Probiotics and Whey Protein Concentrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arla Foods</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arla Foods</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effects of feeding an infant formula containing L. paracasei ssp. paracasei
      strain F19 or Whey Protein Concentrate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Infections episodes (gastrointestinal and upper and lower respiratory infections)</measure>
    <time_frame>4 yrs</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Focus on Healthy Infants</condition>
  <arm_group>
    <arm_group_label>Probiotics F19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>F19 in an infant formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Whey protein concentrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whey protein concentrate in an infant formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <arm_group_label>Probiotics F19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Whey protein concentrate</intervention_name>
    <arm_group_label>Whey protein concentrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria (formula-fed group):

        healthy infants of mothers who could not or voluntarily resigned completely from
        breast-feeding at infant age 14 plus/minus 3 days

        Inclusion criteria (breast-fed group):

        healthy infants exclusively breast-fed from birth and mothers intending to breastfeed &gt;80%
        until at least 5th month of age (meaning through the 4th month of age).

        Inclusion criteria (all infants):

        delivered between 37 and 42 weeks of gestation birth weight &gt;2500 g and &lt;4000 g parent or
        the subject's legal representative speak and understand Chinese

        Exclusion criteria (formula-fed group):

        fully or partially breast-fed infants infants breast-fed &gt;20%

        Exclusion criteria (breast-fed group):

        infants fed &gt;20% infant formula

        Exclusion criteria (all infants):

        malformations, handicaps or congenital diseases that could affect normal  feeding or
        growth treatment with antibiotics
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongmei Peng, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital, Fudan University, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongmei Peng, M.D., Ph.D.,</last_name>
    <email>ympeng99@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaonan Li, M.D., Ph.D.,</last_name>
    <email>xiaonan6189@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Child Health Care, Children's Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongmei Peng, M.D., Ph.D.,</last_name>
      <email>ympeng99@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xiaonan Li, M.D., Ph.D.,</last_name>
      <email>xiaonan6189@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>April 5, 2013</lastchanged_date>
  <firstreceived_date>December 12, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
